Evidence map›Paper›PMID 41836436›Full record

ArticleFrontiers in immunology2026

The capability of deep-radiomics to predict pathological response to neoadjuvant immunochemotherapy in non-small cell lung cancer: a retrospective multicenter study.

Yuanxin Ye, Yuchi Tian, Lingling Wang, Zihan Xi, Yangfan Zhang, Tong Zhou, Zhenhua Zhao, Yifeng Zheng, Xiaoyun Liang, Haitao Jiang

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuanxin Ye *Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.
Yuchi Tian *Institute of Research and Clinical Innovations, Neusoft Medical Systems Co., Ltd, Shanghai, China.
Lingling Wang *Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.
Zihan XiDepartment of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.
Yangfan ZhangDepartment of Radiology, Huzhou Central Hospital, Huzhou, China.
Tong ZhouDepartment of Radiology, Shaoxing People's Hospital, Shaoxing, China.
Zhenhua ZhaoDepartment of Radiology, Shaoxing People's Hospital, Shaoxing, China.
Yifeng ZhengDepartment of Radiology, Huzhou Central Hospital, Huzhou, China.
Xiaoyun LiangInstitute of Research and Clinical Innovations, Neusoft Medical Systems Co., Ltd, Shanghai, China.
Haitao JiangDepartment of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To establish a predictive model that combines radiomics, deep learning and clinical features for predicting the pathological complete response (pCR) of non-small cell lung cancer (NSCLC) patients after neoadjuvant immunochemotherapy (NIT). Methods: We retrospectively collected patients from three centers (split into training, internal testing and external testing cohorts). In this study, tumor segmentation was performed on chest CT images before (pre-NIT) and after (post-NIT) neoadjuvant therapy. The radiomics features were extracted from pre-NIT and post-NIT images. Deep learning (DL) features were extracted from the post-NIT images. The most meaningful features were selected using the mRMR and LASSO. A logistic regression classifier was then applied to create a classification model to predict pCR or non-pCR. The predicted probabilities were referred to as the Rad-scores and Deep-scores. Finally, Rad-scores, Deep-scores, and meaningful clinical features were fused to build a combined model. Results: A total of 178 patients were enrolled in the current study. In conventional radiomics, the efficacy of post-NIT model was better than the pre-NIT. In delta radiomics model, delta1 had the best efficacy. Subsequently, the post-NIT and delta1 features were further constructed as the combined model 1 with AUCs of 0.939 and 0.849, respectively. iRECIST was combined with the radiomics and the DL features to establish the combined model 2, which achieved the best performance among all the models, with AUCs of 0.955(training), 0.882(In-testing), and 0.839(Ex-testing). Conclusions: Our results demonstrated that combination of three dimensional features can provide complementary information to predict pCR more accurately.

Indexed as

Carcinoma, Non-Small-Cell LungDeep LearningLung NeoplasmsNeoadjuvant TherapyRadiomicsAgedFemaleHumansImmunotherapyMaleMiddle AgedPathologic Complete ResponseRetrospective StudiesTomography, X-Ray ComputedTreatment Outcomedeep learningdelta-radiomicsneoadjuvant immunochemotherapyNSCLCpathological complete response

Identifiers

PMID41836436
PMCPMC12982035

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.